Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Publication year range
1.
Acta Pharmaceutica Sinica ; (12): 673-677, 2024.
Article in Chinese | WPRIM (Western Pacific) | ID: wpr-1016628

ABSTRACT

Five flavonoid glycosides were isolated from the methanol and ethyl acetate fractions of the ethanol extract of Diphylleia sinensi by using various chromatographic methods, including silica gel, MCI gel, Sephadex LH-20, ODS and semi-preparative HPLC. The structures of the isolated compounds were identified as diphyflavonoid A (1), diphyflavonoid B (2), quercetin-3-O-β-D-glucopyranoside (3), kaempferol-3-O-β-D-glucopyranoside (4), kaempferol-3-O-(6″-O-acetyl)-β-D-glucopyranoside (5) by spectroscopy methods (1D NMR, 2D NMR, UV, IR, and MS). Compounds 1 and 2 were two new flavonoid glycosides, and compounds 3 and 5 were isolated from the genus Diphylleia for the first time.

2.
Acta Pharmaceutica Sinica ; (12): 605-615, 2023.
Article in Chinese | WPRIM (Western Pacific) | ID: wpr-965615

ABSTRACT

Acute myeloid leukemia (AML) is a genetic heterogeneous disease in which primordial and juvenile myeloid cells proliferate or accumulate abnormally in bone marrow, peripheral blood and other tissues, resulting in damage to normal hematopoietic function. Studies have shown that about 30% of AML patients have FMS-like tyrosine kinase 3 (FLT3), FLT3 abnormal regulation is closely related to the occurrence and development of AML. At present, FLT3 has become an important target for developing small molecular targeted drugs. Currently, a variety of FLT3 inhibitors and FLT3 degraders have been developed targeting FLT3, and some compounds have exhibited good anti-AML activity. This article summarizes and sorts out the current mainstream drugs for AML therapeutic targeting FLT3, in order to provide a reference for the development and design of AML drugs.

3.
Nat Prod Res ; 33(18): 2655-2661, 2019 Sep.
Article in English | MEDLINE | ID: mdl-29737867

ABSTRACT

Three new glycosides (1-3), together with six known ones (4-9), were isolated from the root bark of Lycium chinense. Their structures were elucidated on the basis of MS and NMR spectroscopic data. Five compounds (3, 5, 6, 8, and 9) exhibited potent antihyperlipidemic activities in HepG2 cells as assessed by Oil Red O staining and significant inhibition of intracellular triglyceride (TG) levels, whereas two compounds (5 and 9) significantly reduced total cholesterol (TC) levels.


Subject(s)
Glycosides/chemistry , Glycosides/pharmacology , Hypolipidemic Agents/pharmacology , Lycium/chemistry , Cholesterol/metabolism , Drug Evaluation, Preclinical/methods , Hep G2 Cells , Humans , Hypolipidemic Agents/chemistry , Magnetic Resonance Spectroscopy , Molecular Structure , Plant Bark/chemistry , Plant Extracts/chemistry , Spectrometry, Mass, Electrospray Ionization , Triglycerides/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL
...